上海市卫生和健康发展研究中心主任、医改专家金春林：仿制药“不唯低价”将对价格“内卷”进行纠偏

Core Viewpoint - The National Healthcare Security Administration's decision on July 24 to not solely rely on the lowest bid for the 11th batch of centralized procurement will address the industry's price "involution" issues, promoting a comprehensive evaluation that prioritizes quality while aiming to reduce costs [1] Group 1: Policy Impact - The new policy on generic drugs emphasizes that price is not the only determining factor, which, along with previous encouragement for innovative drug pricing, is expected to positively influence the capital market [1] - These combined policies are anticipated to foster the prosperity and development of the biopharmaceutical industry [1]